<DOC>
	<DOCNO>NCT01055314</DOCNO>
	<brief_summary>This randomize pilot clinical trial study side effect well give temozolomide cixutumumab together combination chemotherapy work treat patient metastatic rhabdomyosarcoma . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cixutumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving temozolomide cixutumumab together combination chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Temozolomide , Cixutumumab , Combination Chemotherapy Treating Patients With Metastatic Rhabdomyosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility administer IMC-A12 ( cixutumumab ) combination multi-agent intensive chemotherapy regimen treatment high-risk rhabdomyosarcoma ( RMS ) . II . To determine feasibility add temozolomide vincristine ( vincristine sulfate ) /irinotecan ( irinotecan hydrochloride ) cycle patient high-risk RMS . III . To assess immediate short-term side effect delivery concurrent temozolomide-vincristine-irinotecan irradiation patient high-risk RMS . SECONDARY OBJECTIVES : I . To gain preliminary estimate response rate IMC-A12 temozolomide plus vincristine/irinotecan previously untreated high-risk RMS . II . To obtain preliminary efficacy data IMC-A12 temozolomide combination multi-agent interval compress chemotherapy regimen previously untreated high-risk RMS . III . To determine effectiveness detect metastatic disease fludeoxyglucose F 18 positron emission tomography ( FDG PET ) compare assessment response use standard image technique response assess FDG PET . IV . To assess change serum level insulin-like growth factor ( IGF ) -I , IGF-II , IGF-BP3 biomarkers IGF-IR inhibition . OUTLINE : This dose-escalation study cixutumumab . Patients assign 1 2 treatment group accord time enrollment onto study . GROUP 1 : Patients receive vincristine sulfate intravenously ( IV ) 1 minute day 1 week 1-5 , 7 , 8 , 11 , 12 , 15 , 16 , 20-24 , 28 , 29 , 32 , 33 , 35 , 38 , 41-44 , 47 , 48 , 50 , 51 ; irinotecan hydrochloride IV 90 minute day 1-5 week 1 , 4 , 20 , 23 , 47 , 50 ; ifosfamide IV 1 hour etoposide IV 1-2 hour day 1-5 week 9 , 13 , 17 , 26 , 30 ; doxorubicin hydrochloride IV 1-15 minute day 1 2 week 7 , 11 , 15 , 28 , 32 ; cyclophosphamide IV 30-60 minute day 1 week 7 , 11 , 15 , 28 , 32 , 35 , 38 , 41 , 44 ; dactinomycin IV 1-5 minute day 1 week 35 , 38 , 41 , 44 ; cixutumumab IV 1 hour day 1 week 1-51 . Patients also undergo radiation therapy* day 1-5 week 20-24 . GROUP 2 : Patients receive vincristine sulfate , irinotecan hydrochloride , ifosfamide , etoposide , doxorubicin hydrochloride , cyclophosphamide , dactinomycin undergo radiation therapy* group 1 . Patients also receive temozolomide orally ( PO ) day 1-5 week 1 , 4 , 20 , 23 , 47 , 50 . GROUP 3 : Patients receive vincristine sulfate , irinotecan hydrochloride , ifosfamide , etoposide , doxorubicin hydrochloride , cyclophosphamide , dactinomycin , cixutumumab undergo radiation therapy* group 1 . Patients also receive temozolomide group 2 . ( Discontinued January 2013 ) NOTE : *Patients parameningeal tumor evidence intracranial extension require emergency radiotherapy may receive radiation therapy start week 1 ; cixutumumab withheld radiation therapy . After completion study therapy , patient follow 3 week periodically 5 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Alveolar</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must eligible , enrol D9902 prior enrollment ARST08P1 Patients newly diagnose , biopsyproven metastatic rhabdomyosarcoma ectomesenchymoma ( stage IV , clinical group IV ) eligible study ; patient stage IV , clinical group IV RMS parameningeal paraspinal primary tumor , include intracranial extension ( ICE ) eligible ARST08P1 ; ICE define contrast magnetic resonance imaging ( MRI ) show primary tumor touch , displaces , invades , distorts , otherwise cause signal abnormality dura brain spinal cord contiguity primary site ; ICE also presume exist cerebrospinal fluid ( CSF ) cytopathology positive tumor diagnosis Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 , 2 ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age No prior chemotherapy radiotherapy except use corticosteroid emergent radiation therapy ; patient require emergency radiation eligible Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73m^2 OR maximum serum creatinine base age/gender follow : 0.4 mg/dL ( patient 1 5 month age ) 0.5 mg/dL ( patient 6 11 month age ) 0.6 mg/dL ( patient 1 year age ) 0.8 mg/dL ( patient 2 5 year age ) 1.0 mg/dL ( patient 6 9 year age ) 1.2 mg/dL ( patient 10 12 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient 13 15 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient &gt; = 16 year age ) Patients urinary tract obstruction tumor must meet renal function criterion list AND must unimpeded urinary flow establish via decompression obstruct portion urinary tract Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age , unless evidence biliary obstruction tumor Shortening fraction &gt; = 27 % echocardiogram ( ECHO ) OR ejection fraction &gt; = 50 % radionuclide angiogram Absolute neutrophil count ( ANC ) &gt; = 750/uL ; abnormal blood count permissible bone marrow biopsy aspirate proven bone marrow involvement rhabdomyosarcoma Platelet count &gt; = 75,000/uL ; abnormal blood count permissible bone marrow biopsy aspirate proven bone marrow involvement rhabdomyosarcoma Sexually active patient childbearing potential must agree use effective contraception therapy ( Pilots 1 2 ) least 3 month last dose IMCA12 ( Pilots 1 ) Female patient pregnant eligible Female patient breastfeed eligible ; female patient lactate must agree stop breastfeed participate study Patients receive growth hormone therapy eligible Patients know type I type II diabetes mellitus eligible enrollment Pilot 1 Patients evidence uncontrolled infection eligible All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>